Functional characterization of YM928, a novel noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 1, 2003, Pages 66-72

  Ohno, Kazushige ^a   Tsutsumi, Rie ^a   Matsumoto, Naoyuki ^a   Yamashita, Hiroshi ^a   Amada, Yoko ^a   Shishikura, Jun Ichi ^a   Inami, Hiroshi ^a   Yatsugi, Shin Ichi ^a   Okada, Masamichi ^a   Sakamoto, Shuichi ^a   Yamaguchi, Tokio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; CALCIUM ION; FURA 2 ACETOXYMETHYL ESTER; TALAMPANEL; VERATRIDINE; YM 928;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN FUNCTION; BRAIN MEMBRANE; CALCIUM CELL LEVEL; COMPETITIVE INHIBITION; DRUG EFFECT; HIPPOCAMPUS; LIGAND BINDING; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; BINDING, COMPETITIVE; CALCIUM; CELLS, CULTURED; EXCITATORY AMINO ACID ANTAGONISTS; KAINIC ACID; MALE; MICE; MICE, INBRED DBA; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, AMPA; THIAZINES;

EID: 0038613421     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.049973     Document Type: Article

References (37)

1. Buchan AM, Xue D, Huang ZG, Smith KH, and Lesiuk H (1991) Delayed AMPA receptor blockage reduces cerebral infarction induced by focal ischemia. Neuroreport 2:473-476.
2. Bullock R, Graham DI, Swanson S, and McCulloch J (1994) Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab 14:466-471.
3. Chapman AG, Smith SE, and Meldrum BS (1991) The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI52466, in mice. Epilepsy Res 9:92-96.
4. Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, Bjerke J, Kiesler GM, and Arroyo S (2002) A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 58:1680-1682.
5. De Sarro GB, Meldrum BS, and Nistico G (1988) Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. Br J Pharmacol 93:247-256.
6. Durmuller N, Craggs M, and Meldrum BS (1994) The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdalakindled seizures. Epilepsy Res 17:167-174.
7. Gill R, Brazell C, Woodruff GN, and Kemp JA (1991) The neuroprotective action of dizocilpine (MK801) in the rat middle cerebral artery occlusion model of focal ischaemia. Br J Pharmacol 103:2030-2036.
8. Gill R, Kemp JA, Richards JG, and Kew JNC (1999) NMDA receptor antagonists: past disappointments and future prospects as neuroprotective agents. Curr Opin Cardiovasc Pulm Renal Investig Drugs 1:576-591.
9. Gill R, Nordholm L, and Lodge D (1992) The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) in a rat focal ischaemia model. Brain Res 580:35-43.
10. Graham SH, Chen J, Lan JQ, and Simon RP (1996) A dose-response study of neuroprotection using the AMPA antagonist, NBQX, in rat focal ischemia. J Pharmacol Exp Ther 276:1-4.
11. Judge ME, Sheardown MJ, Jacobsen P, and Honoré T (1991) Protection against post-ischemic behavioral pathology by the α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionic acid (AMPA) antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) in the gerbil. Neurosci Lett 133:291-294.
12. Koek W, Wood JH, and Winger GD (1988) MK801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission produces phencyclidinelike behavioral effects in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 245:969-974.
13. Kohara A, Okada M, Tsutsumi R, Ohno K, Takahashi M, Shimizu-Sasamata M, Shishikura J, Inami H, Sakamoto S, and Yamaguchi T (1998) In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist. J Pharm Pharmacol 50:795-801.
14. Lazzaro JT, Paternain AV, Lerma J, Chenard BL, Ewing FE, Huang J, Welch WM, Ganong AH, and Menniti FS (2002) Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology 42:143-153.
15. Lees GJ (2000) Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs 59:33-78.
16. Le Peillet E, Arvin B, Moncada C, and Meldrum BS (1992) The non-NMDA antagonists, NBQX and GYKI52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat. Brain Res 571:115-120.
17. Li H and Buchan AM (1993) Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury. J Cereb Blood Flow Metab 13:933-939.
18. Lodge D, Bond A, O'Neill MJ, Hicks CA, and Jones MG (1996) Stereoselective effects of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Neuropharmacology 35:1681-1688.
19. Menniti FS, Chenard BL, Collins MB, Ducat MF, Elliott ML, Ewing FE, Huang JI, Kelly KA, Lazzaro JT, Pagnozzi MJ, et al. (2000) Characterization of the binding site for a novel class of noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists. Mol Pharmacol 58:1310-1317.
20. Morris RGM, Anderson E, Lynch GS, and Baudry M (1986) Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature (Lond) 319:774-776.
21. Mukawa J and Jinnai D (1970) A clinical experience of B169, a new anti-epileptic drug. Seishin Igaku 12:625-630.
22. Nikam SS and Kornberg BE (2001) AMPA receptor antagonists. Curr Med Chem 8:155-170.
23. 2+ fluorometry. Neurosci Lett 78:69-74.
24. Ohno K, Okada M, Tsutsumi R, Kohara A, and Yamaguchi T (1997) Kainate excitotoxicity is mediated by AMPA- but not kainate-preferring receptors in embryonic rat hippocampal cultures. Neurochem Int 31:715-722.
25. Ohno K, Okada M, Tsutsumi R, Matsumoto N, and Yamaguchi T (1998) Characterization of cyclothiazide-enhanced kainate excitotoxicity in rat hippocampal cultures. Neurochem Int 32:265-271.
26. Olney JW, Labruyere J, and Price MT (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science (Wash DC) 244:1360-1362.
27. O'Neill MJ, Bond A, Ornstein PL, Ward MA, Hicks CA, Hoo K, Bleakman D, and Lodge D (1998) Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacology 37:1211-1222.
28. Park CK, Nehls DG, Graham DI, Teasdale GM, and McCulloch J (1988) The glutamate antagonist MK801 reduces focal ischemic brain damage in the rat. Ann Neurol 24:543-551.
29. Seeburg EH (1993) The molecular biology of mammalian glutamate receptor channels. Trends Neurosci 16:359-365.
30. Seki T and Fukuyama Y (1971) Clinical evaluation of 2-(beta-pyridyl-(2″)-ethenyl)-3-(2′-methylphenyl)- quinazolinone-(4) (B169) in the treatment of epilepsy. No To Shinkei 23:1087-1092.
31. Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P, and Honore T (1990) 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science (Wash DC) 247:571-574.
32. Sheardown MJ, Suzdak PD, and Nordholm L (1993) AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h. Eur J Pharmacol 236:347-353.
33. Shimizu-Sasamata M, Kawasaki-Yatsugi S, Okada M, Sakamoto S, Yatsugi S, Togami J, Hatanaka K, Ohmori J, Koshiya K, Usuda S, et al. (1996) YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist. J Pharmacol Exp Ther 276:84-92.
34. Smith SE, Durmuller N, and Meldrum BS (1991) The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol 201:179-183.
35. Smith SE and Meldrum BS (1992) Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI52466, after focal ischaemia in the rat. Stroke 23:861-864.
36. Xue D, Huang ZG, Barnes K, Lesiuk HJ, Smith KE, and Buchan AM (1994) Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J Cereb Blood Flow Metab 14:251-261.
37. Yamaguchi S, Donevan SD, and Rogawski MA (1993) Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res 15:179-184.